For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 53,140 | 57,877 | 57,843 | |
| Selling, general and administrative | 18,728 | 26,414 | 32,579 | |
| Total operating expenses | 71,868 | 84,291 | 90,422 | |
| Loss from operations | -71,868 | -84,291 | -90,422 | |
| Research and development incentives | 341 | 377 | 420 | |
| Investment income | 2,846 | 3,696 | 4,714 | |
| Interest expense on finance lease liability | 514 | 518 | 521 | |
| Interest expense on debt obligations | 1,466 | 1,488 | 1,475 | |
| Other (expense) income, net | -580 | -876 | 591 | |
| Total other income (expense), net | 627 | 1,191 | 3,729 | |
| Loss before income taxes | -71,241 | - | - | |
| Income tax (benefit) provision | -311 | - | - | |
| Net loss | -70,930 | -83,100 | -86,693 | |
| Basic EPS | -0.77 | -0.9 | -0.95 | |
| Diluted EPS | -0.77 | -0.9 | -0.95 | |
| Basic Average Shares | 92,187,581 | 91,915,769 | 91,516,199 | |
| Diluted Average Shares | 92,187,581 | 91,915,769 | 91,516,199 | |
Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL)